NME Blockbuster Approvals — October 16, 2026

FDA approved PRITELIVIR (HOVILPR) under Priority Review, a 6-month review pathway that the FDA typically reserves for applications it views as offering significant improvement over existing therapy. Peak sales, exclusivity duration, and pricing are NOT_DISCLOSED in the source data.

The approval is recorded with a FALLBACK approval-type tag alongside an NME classification, creating an inconsistency that should be resolved against the FDA action letter before drawing firm conclusions about the regulatory pathway and exclusivity treatment for PRITELIVIR.

PRITELIVIR (HOVILPR) commercial launch by AICURIS Anti-Infective Cures AG following Priority Review approval, with market entry and payer coverage dynamics to be established.

A single anti-infective NME (PRITELIVIR) received Priority Review approval in this window, which is too few events to establish a sector trend. The approval is noted as a single data point rather than evidence of a broader cluster.

{"entity" => "PRITELIVIR (HOVILPR)", "reason" => "Priority Review NME approval with bullish signal (strength 8/10, materiality 8/10), but commercial parameters including peak sales, exclusivity, pricing power, and market position are all NOT_DISCLOSED.", "trigger" => "Commercial launch announcement and WAC pricing disclosure; any confirmatory trial or post-marketing commitment disclosures from the FDA action letter"}

{"entity" => "AICURIS Anti-Infective Cures AG", "reason" => "Sponsor of the sole approval in this period; pipeline depth cannot be assessed from a single approval event.", "trigger" => "Next PDUFA date disclosure and any additional NDA or BLA submissions in the sponsor's pipeline"}